Literature DB >> 20950509

Hearing and ossicular chain preservation in cholesteatoma surgery.

R Obholzer1, J Ahmed, F Warburton, M J Wareing.   

Abstract

OBJECTIVE: To assess the hearing changes associated with sacrificing an intact ossicular chain during cholesteatoma surgery.
METHODS: We reviewed the operation notes of surgical procedures performed by the senior author between October 2000 and April 2006. Thirty-three cases were identified in which cholesteatoma surgery had been performed in the presence of a mobile, intact ossicular chain. One set of case notes was missing; therefore, 32 cases were included in the analysis. The ossicular chain was preserved in 17 cases (14 males and three females) and sacrificed in 15 (eight males and seven females).
RESULTS: At the first post-operative assessment, a median air-bone gap deterioration of 3.3 dB was seen in patients in whom the ossicular chain had been sacrificed, while a median air-bone gap improvement of 3.3 dB was seen in those in whom the chain had been preserved. However, multivariable logistic regression analysis suggested that this difference in hearing outcomes was due to pre-operative hearing status, and that preservation of the ossicular chain did not lead to a better outcome.
CONCLUSIONS: In cholesteatoma surgery, there is at most a marginal benefit in preserving the ossicular chain. In the current study, the better hearing outcomes associated with preservation of the ossicular chain were accounted for by patients' better pre-operative hearing status. This study did not demonstrate a difference in residual disease rate, but was underpowered to do so.

Entities:  

Mesh:

Year:  2010        PMID: 20950509     DOI: 10.1017/S0022215110002021

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

1.  The Effect of the Status of the Ossicular Chain and Choice of Graft Material on Hearing Outcomes in Pediatric Cholesteatoma Surgery.

Authors:  Eiko Kimura; Colin G Leonard; Adrian L James
Journal:  J Int Adv Otol       Date:  2021-03       Impact factor: 1.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.